Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › retinal diseases

Retinal diseases

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for retinal diseases

4 trials tracked for retinal diseases: 1 in phase 3 or 4 and 1 with published results. The most-cited published study has 4 citations.

4Trials tracked
1Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 3 1 Phase 2 3
  1. Phase 3 Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD Completed · 4 cited
  2. Phase 2 Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE) Completed
  3. Phase 2 High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia Completed
  4. Phase 2 INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD Completed

Showing the 4 most-cited and recently-updated of 4 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Medicinal mushroom-derived compounds show potential for managing oxidative stress and inflammation in ocular conditions
Drug Pipeline Sys. Review
Medicinal mushroom-derived compounds show potential for managing oxidative stress and inflammation in ocular conditions Medicinal mushrooms show promise for several common eye conditions
This narrative review synthesizes evidence regarding medicinal mushroom-derived bioactive compounds, including polysaccharides and triterpen…
Medicinal mushrooms contain compounds that may protect the eyes from inflammation and damage, though more clinical trials are needed to conf…
Frontiers Sep 15, 2026
Budget impact analysis of switching to ranibizumab biosimilar for retinal diseases in Jordan
Orthopedics & Sports Medicine Guideline
Budget impact analysis of switching to ranibizumab biosimilar for retinal diseases in Jordan Jordan Eye Drug Biosimilar Slashes Costs and Boosts Patient Access
This budget impact analysis from a Jordanian public sector perspective estimates that switching from aflibercept to ranibizumab's biosimilar…
Switching to a biosimilar version of a common eye drug could save Jordan’s public health system millions and help more patients get treatmen…
Frontiers May 8, 2026